Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meladrazine
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Meladrazine is a pharmaceutical agent that has been investigated for its anticholinergic properties, primarily in the treatment of urinary symptoms such as detrusor hyperreflexia and urge incontinence. Clinical trials explored its efficacy in patients with multiple sclerosis and geriatric patients, though its use was often limited by a high incidence of side effects. Beyond its therapeutic applications, Meladrazine is also utilized as a derivatizing reagent in mass spectrometry-based methodologies for the analysis of glycans, particularly in enhancing the detection of fucosylated glycans.
- Brand names
- Lisidonil
- Other names
- Meladrazine Tartrate
02
Targets
mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on Meladrazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meladrazine.